Karyopharm Therapeutics Inc. is a pharmaceutical company primarily engaged in the development and commercialization of novel cancer therapies. The company's main focus lies in advancing selective inhibitors of nuclear export (SINE) compounds, which target proteins involved in the regulation of cell growth and survival, making them particularly relevant to the treatment of various malignancies. Karyopharm Therapeutics' innovative approach contributes significantly to oncology, offering potential new treatments for conditions with unmet medical needs. The impact of their work spans across multiple sectors in the healthcare industry, including research and development, biotechnology, and pharmaceutical manufacturing. Karyopharm's flagship product, FDA-approved for specific indications, underscores its role in the competitive oncology market by introducing pioneering therapeutic options. Headquartered in Newton, Massachusetts, Karyopharm Therapeutics continues to play a pivotal role in expanding the landscape of cancer treatment, thereby influencing market dynamics and facilitating advances in patient care outcomes.